乳腺浸润性导管癌中BCRP、HIF-1α、HER-2的表达及其相关性与临床意义

目的探讨乳腺浸润性导管癌组织中乳腺癌耐药蛋白（BCRP）、缺氧诱导因子-1α（HIF-1α）、人类表皮生长因子受体-2（HER-2）的表达及临床意义。方法应用ElivisionTM plus免疫组织化学法检测75例乳腺浸润性导管癌组织及15例癌旁正常组织中BCRP、HIF-1α、HER-2蛋白的表达情况。结果（1）75例乳腺浸润性导管癌中BCRP、HIF-1α、HER-2阳性表达分别为41.3%（31/75）、61.3%（46/75）和26.7%（20/75）;除了BCRP在癌旁正常组织中有一定程度的表达外13.3%（2/15）,HIF-1α、HER-2未见表达。（2）BCRP与HIF-1α之间（r=0.205,P=0.011）,HIF-1α与HER-2之间（r=0.349,P=0.000）有相关性;BCRP与HER-2之间（r=0.155,P=0.059）无相关性。（3）BCRP表达与年龄、TNM分期、肿瘤大小、腋淋巴结转移状况及激素受体状况均无关;HIF-1α、HER-2的表达与TNM分期及腋淋巴结转移状况有关,而与年龄、肿瘤大小及激素受体表达状况无关。结论BCRP与乳腺浸润性导管癌原发多药耐药（MDR）的发生有关,HIF-1α可能参与了BCRP基因的调节机制,HER-2在某种程度上也可能参与了MDR,化疗前对它们进行联合检测可为化疗药物的选择及预后判断提供参考。

xpression of BCRP,HIF-1α and HER-2 in Invasive Ductal Carcinoma of Breast and the Correlation with Clinical Significance

Objectives To investigate the expressions of BCRP, HIF-1α and HER-2 and their correlation in invasive ductal carcinoma of breast,so as to elucidate their relationship with breast cancer clinicoPathologic Parameters. Methods Expressions of BCRP, HIF-1α and HER-2 were detected in 75 cases of breast cancer tissue and 15 cases of normal tissue with Elivision^TM plus immunohistochemistry. Results （1）The positive expression rate of BCRP, HIF-1α and HER-2 was respectively 41.3%（31/75）,61.3%（46/75）and 26.7%（20/75）. The positive rate of BCRP was 13.3% （2/15） in normal tissue,while no expression of HIF-1α and HER-2 was observed. （2）Expression of BCRP was correlated with expression of HIF-1α（r=0. 205 ,P=0. 011） ,and expression of HIF-1α was correlated with expression of HER-2（r=0. 349 ,P=0. 000） ,whereas there was no corelation between BCRP and HER-2（r= 0. 155, P=0. 059）. （3）The expression levels of BCRP didn＇t correlate with clinical pathologic parameters. HIF-1α and HER-2 were significantly corre-lated with the clinical TNM stage and lymph node status,while had no correlation with, age,tumor size and the status of ER and PR. Conclusions It suggests that the expression of BCRP is related to the primary multidrug resistance of breast carcinoma tissues and HIF-1α may be involved in the regulatory mechanism of BCRP gene,and HER-2 may play a role in MDR. Detecting the expression of the three genes prior to chemotherapy would provide evidence for the selection of drugs and for the judgement of the prognosis.